Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis

IF 4.3 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Helicobacter Pub Date : 2025-02-04 DOI:10.1111/hel.70014

Asaf Ness, Zohar Levi, Rachel Gingold Belfer, Ram Dickman, Doron Boltin

{"title":"Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis","authors":"Asaf Ness, Zohar Levi, Rachel Gingold Belfer, Ram Dickman, Doron Boltin","doi":"10.1111/hel.70014","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Glucagon-like peptide-1 (GLP-1) receptor agonists delay gastric emptying and are used for the treatment of diabetes (DM) and obesity. Successful treatment of <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection depends upon a precise dosing schedule. We aimed to examine the impact of GLP-1 drugs on antibiotic treatment for <i>H. pylori</i>.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Adults with a new diagnosis of <i>H. pylori</i> infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database. Subjects were divided into groups based on diagnoses of DM and obesity, and exposure to GLP-1 drugs. A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified 426 individuals who received, and 36,436 who did not receive GLP-1 drugs. Eradication among those who did and did not receive GLP-1 drugs was 86.6% and 83.7%, respectively (<i>p =</i> 0.059 across subgroups). Eradication among those who received semaglutide was 93.8% (OR 2.78, 95% CI 1.32–5.83, <i>p</i> = 0.007). Eradication in subjects who received dulaglutide (88.6%) or liraglutide (81.4%) was not significantly changed. When applying a propensity-score-adjusted analysis, eradication remained significantly increased among individuals who received semaglutide (OR 2.89, 95% CI 1.24–6.74, <i>p</i> = 0.014). Additional independent predictors of successful eradication included male sex, high socioeconomic status, quadruple therapy, and older age (<i>p <</i> 0.001 for all).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Co-administration of semaglutide and antibiotics for <i>H. pylori</i> infection is associated with an increased likelihood of successful eradication.</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"30 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.70014","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.70014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Glucagon-like peptide-1 (GLP-1) receptor agonists delay gastric emptying and are used for the treatment of diabetes (DM) and obesity. Successful treatment of Helicobacter pylori (H. pylori) infection depends upon a precise dosing schedule. We aimed to examine the impact of GLP-1 drugs on antibiotic treatment for H. pylori.

Methods

Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database. Subjects were divided into groups based on diagnoses of DM and obesity, and exposure to GLP-1 drugs. A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.

Results

We identified 426 individuals who received, and 36,436 who did not receive GLP-1 drugs. Eradication among those who did and did not receive GLP-1 drugs was 86.6% and 83.7%, respectively (p = 0.059 across subgroups). Eradication among those who received semaglutide was 93.8% (OR 2.78, 95% CI 1.32–5.83, p = 0.007). Eradication in subjects who received dulaglutide (88.6%) or liraglutide (81.4%) was not significantly changed. When applying a propensity-score-adjusted analysis, eradication remained significantly increased among individuals who received semaglutide (OR 2.89, 95% CI 1.24–6.74, p = 0.014). Additional independent predictors of successful eradication included male sex, high socioeconomic status, quadruple therapy, and older age (p < 0.001 for all).

Conclusions

Co-administration of semaglutide and antibiotics for H. pylori infection is associated with an increased likelihood of successful eradication.

Abstract Image

查看原文本刊更多论文

接受西马鲁肽的成人幽门螺杆菌根除的改善：基于人群的倾向评分调整分析

胰高血糖素样肽-1 （GLP-1）受体激动剂可延迟胃排空，用于治疗糖尿病（DM）和肥胖。幽门螺杆菌感染的成功治疗取决于精确的给药计划。我们的目的是研究GLP-1药物对幽门螺杆菌抗生素治疗的影响。方法在Clalit Health Services数据库中筛选2014 - 2023年间接受治疗的新诊断为幽门螺杆菌感染的成人。根据糖尿病和肥胖的诊断以及GLP-1药物的暴露程度，将受试者分为不同的组。使用1:2倾向评分匹配数据集来确定GLP-1药物对根除成功的影响。结果426人接受GLP-1药物治疗，36436人未接受GLP-1药物治疗。接受GLP-1药物治疗和未接受GLP-1药物治疗的根除率分别为86.6%和83.7%（亚组间p = 0.059）。接受西马鲁肽治疗的患者根除率为93.8% （OR 2.78, 95% CI 1.32-5.83, p = 0.007）。接受杜拉鲁肽（88.6%）或利拉鲁肽（81.4%）治疗的受试者根除率无显著变化。当应用倾向评分校正分析时，接受西马鲁肽的个体根除率仍然显著增加（OR 2.89, 95% CI 1.24-6.74, p = 0.014）。成功根除的其他独立预测因素包括男性、高社会经济地位、四联疗法和年龄较大（所有p <； 0.001）。结论：西马鲁肽联合抗生素治疗幽门螺杆菌感染与成功根除的可能性增加有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Helicobacter 医学-微生物学

CiteScore

8.40

自引率

9.10%

发文量

审稿时长

2 months

期刊介绍： Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.